BIO3 Stock Overview
Biotest Aktiengesellschaft desarrolla, fabrica y vende productos farmacéuticos biológicos y biotecnológicos en Alemania y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €29.40 |
| 52 Week High | €32.20 |
| 52 Week Low | €25.20 |
| Beta | 0.26 |
| 1 Month Change | 5.76% |
| 3 Month Change | -4.55% |
| 1 Year Change | -2.65% |
| 3 Year Change | -2.00% |
| 5 Year Change | 33.33% |
| Change since IPO | 25.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIO3 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 8.9% | -1.2% | 0.4% |
| 1Y | -2.6% | -5.7% | 3.5% |
Rentabilidad frente al sector: BIO3 superó al sector Austrian Biotechs , que obtuvo un rendimiento del -3.9% el año pasado.
Rentabilidad vs. Mercado: BIO3 obtuvo unos resultados inferiores a los del mercado Austrian, que fue del 3.3% el año pasado.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.2% |
| 10% most volatile stocks in AT Market | 5.3% |
| 10% least volatile stocks in AT Market | 1.6% |
Precio estable de las acciones: BIO3 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: BIO3(5%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de Austrian.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 2,426 | Peter Janssen | https://www.biotest.com |
Biotest Aktiengesellschaft desarrolla, fabrica y vende productos farmacéuticos biológicos y biotecnológicos en Alemania y a escala internacional. Opera a través de tres segmentos: Unión Europea, Resto del Mundo y Apátridas. La empresa se especializa principalmente en las áreas terapéuticas de inmunología clínica, hematología y medicina intensiva.
Biotest Aktiengesellschaft Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market cap | €1.41b |
| Earnings (TTM) | €127.00m |
| Revenue (TTM) | €684.60m |
9.1x
P/E Ratio1.7x
P/S RatioIs BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €684.60m |
| Cost of Revenue | €404.30m |
| Gross Profit | €280.30m |
| Other Expenses | €153.30m |
| Earnings | €127.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | 3.21 |
| Gross Margin | 40.94% |
| Net Profit Margin | 18.55% |
| Debt/Equity Ratio | 126.7% |
How did BIO3 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield1%
Payout RatioDoes BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarks| Biotest dividend dates | |
|---|---|
| Ex Dividend Date | May 08 2024 |
| Dividend Pay Date | May 13 2024 |
| Days until Ex dividend | 32 days |
| Days until Dividend pay date | 37 days |
Does BIO3 pay a reliable dividends?
See BIO3 dividend history and benchmarks